A comparison between vaginal prostaglandin E2 suppositories and intrauterine extra-amniotic prostaglandins in the management of fetal death in utero
| Autor: | Thomas D. Kerenyi, Dai-Yun Jeng, Jonathan Scher, Jasmin Moshirpur |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
Adult
medicine.medical_specialty Time Factors medicine.medical_treatment Incomplete Abortion Pregnancy Medicine Humans Amnion Prostaglandin E2 Abortion Therapeutic Fetal Death Gynecology business.industry Prostaglandins E Suppositories Obstetrics and Gynecology medicine.disease Uterine rupture Diarrhea Oxytocin In utero Vagina Vomiting Female medicine.symptom business medicine.drug Prostaglandin E |
| Zdroj: | American journal of obstetrics and gynecology. 137(7) |
| ISSN: | 0002-9378 |
| Popis: | This retrospective study was undertaken to compare the efficacy, side effects, and complications of prostaglandin E 2 (PGE 2 ) given as a vaginal suppository with those of PGE 2 administered via the intrauterine extra-amniotic route to induce labor after fetal death. The induction-to-delivery intervals were comparable, with 9.2 ± 3.94 hours and 8.6 ± 4.49 hours, respectively. However, the mean total amount of PGE 2 administered was much less via the intrauterine extra-amniotic route (1.8 milligrams) than by the vaginal suppository (45.2 mg). There was a 100% success rate in the patients treated by the intrauterine extra-amniotic route, but only a 91.3% success rate in those patients treated via the vaginal route. The side effects (vomiting, diarrhea, fever) and the complications (incomplete abortion, uterine rupture, oxytocin augmentation) occurred more frequently with the use of PGE 2 as a vaginal suppository. The vaginal route of administration of PGE 2 is somewhat more convenient, but the intrauterine extra-amniotic route may offer a higher degree of efficacy and safety with fewer side effects in the management of fetal death in utero. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|